pegfilgrastim

This page shows the latest pegfilgrastim news and features for those working in and with pharma, biotech and healthcare.

Amgen buys Danish partner Nuevolution for $167m

The company is starting to face biosimilar competition for white blood cell stimulator Neulasta (pegfilgrastim) as well as generic encroachment on Sensipar (cinacalcet) for secondary hyperparathyroidism, which together accounted for around

Latest news

Amgen CEO says Aimovig is “one of most successful launches”

Overall, Amgen posted a 2% rise in revenues to $5.78bn in the quarter, despite pressure on older drugs like while blood cell booster Neulasta (pegfilgrastim) which showed the first signs
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

The three biosimilars are: Mylan’s Hulio (adalimumab), a version of AbbVie’s big-selling Humira for the treatment of certain inflammatory and autoimmune disorders; and Accord Healthcare’s Pelgraz (pegfilgrastim) ... and ERA Consulting’s Udenyca
Novartis doubles down on biosimilars with Biocon alliance

drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA.
Biocon backs away from biosimilar filings in Europe

white cell booster Neulasta (pegfilgrastim) at the request of the EMA.
Novartis says its biosimilar sales should reach $1bn this year

The biosimilar is also under review in Europe. Meanwhile, Novartis confirmed that it will have to carry out a new clinical trial on its biosimilar version of Amgen's Neulasta (pegfilgrastim),